Histogenics Corp. (NASDAQ:HSGX) shares traded up 11.9% during mid-day trading on Monday . The stock traded as high as $2.17 and last traded at $2.07, with a volume of 119,552 shares. The stock had previously closed at $1.85.

Several research analysts have issued reports on the stock. BTIG Research reiterated a “hold” rating on shares of Histogenics Corp. in a report on Sunday, May 15th. Canaccord Genuity restated a “buy” rating on shares of Histogenics Corp. in a report on Thursday, May 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $12.13.

The firm’s 50 day moving average price is $1.86 and its 200-day moving average price is $2.33. The stock’s market cap is $26.01 million.

Histogenics Corp. (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.01. During the same quarter in the previous year, the firm posted ($0.60) EPS. On average, equities analysts predict that Histogenics Corp. will post ($2.15) earnings per share for the current fiscal year.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.